Results 31 to 40 of about 1,444,670 (278)

Cardiomyocyte Overexpression of FABP4 Aggravates Pressure Overload-Induced Heart Hypertrophy. [PDF]

PLoS ONE, 2016
Fatty acid binding protein 4 (FABP4) is a member of the intracellular lipid-binding protein family, responsible for the transportation of fatty acids.
Ji Zhang, Congzhen Qiao, Lin Chang, Yanhong Guo, Yanbo Fan, Luis Villacorta, Y Eugene Chen, Jifeng Zhang   +7 more
doaj   +1 more source

Efficacy and Safety of Selective Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: a Meta-analysis [PDF]

Zhongguo quanke yixue
Background Hypertrophic cardiomyopathy (HCM) is a genetic disorder, characterized primarily by left ventricular outflow tract obstruction and asymmetric myocardial hypertrophy, which predisposes to sudden cardiac death and malignant arrhythmias. Although
ZHANG Huijuan, LI Xinghui, ZHANG Xiaoming, YIN Long, SHAO Long
doaj   +1 more source

Aldosterone inhibits the fetal program and increases hypertrophy in the heart of hypertensive mice. [PDF]

PLoS ONE, 2012
BACKGROUND: Arterial hypertension (AH) induces cardiac hypertrophy and reactivation of "fetal" gene expression. In rodent heart, alpha-Myosin Heavy Chain (MyHC) and its micro-RNA miR-208a regulate the expression of beta-MyHC and of its intronic miR-208b.
Feriel Azibani, Yvan Devaux, Guillaume Coutance, Saskia Schlossarek, Evelyne Polidano, Loubina Fazal, Regine Merval, Lucie Carrier, Alain Cohen Solal, Christos Chatziantoniou, Jean-Marie Launay, Jane-Lise Samuel, Claude Delcayre   +12 more
doaj   +1 more source

Cardiac myosin inhibitors in hypertrophic cardiomyopathy

Journal of Cardiovascular Imaging
Abstract Mavacamten, the first selective and reversible cardiac myosin inhibitor (CMI), has been introduced to the clinical arena for the treatment of obstructive hypertrophic cardiomyopathy (HCM). By reducing excessive actin-myosin cross-bridging, this agent decreases myocardial contractility and alleviates the dynamic left ventricular ...
Lim, Jaehyun, Kim, Hyung-Kwan
openaire   +2 more sources

Pinocembrin Protects Cardiomyocytes Against Isoproterenol-Induced Hypertrophy

Natural Product Communications, 2021
Cardiac hypertrophy is characterized by an increase in myocardial cell volume and extracellular matrix production. Persistent cardiac hypertrophy can cause dilated cardiomyopathy, heart failure, and even death.
Xin Sui, Na Li, Xiaozheng Shi, Xiaohua Li, Dong Han, Zhidong Qiu, Yue Deng, Guangwei Sun   +7 more
doaj   +1 more source

Movement of the converter in cardiac myosin

, 2022
Brief video of the movement of the converter in β-cardiac myosin during MD simulation.
Galentino
core   +1 more source

Pyruvate Kinase M2 Protects Heart from Pressure Overload‐Induced Heart Failure by Phosphorylating RAC1

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Heart failure, caused by sustained pressure overload, remains a major public health problem. PKM (pyruvate kinase M) acts as a rate‐limiting enzyme of glycolysis. PKM2 (pyruvate kinase M2), an alternative splicing product of PKM, plays complex
Le Ni, Bowen Lin, Lingjie Hu, Ruoyu Zhang, Fengmei Fu, Meiting Shen, Jian Yang, Dan Shi   +7 more
doaj   +1 more source

Myosin VI Lever Arm Rotation: Fixed or Variable? [PDF]

, 2010
Two recent articles addressed the power-stroke of myosin VI molecules during stepping. Although both groups measured the angles of fluorescent probes attached on the myosin VI molecule lever arm using polarized fluorescence techniques, they differ about ...
Yujie Sun, Harry W. Schroeder III, Kazuaki Homma, John Beausang, Mitsuo Ikebe, Yale Goldman, John F. Beausang, Harry Schroeder III, Yale E. Goldman   +8 more
core   +1 more source

Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials

Open Heart
Background Unlike other suggested therapies, myosin inhibitors have been shown to change the course of hypertrophic cardiomyopathy by altering the contractile mechanics of cardiomyocytes.
Ayesha Aman, Arfa Akram, Bisma Akram, Momina Maham, Masooma Zainab Bokhari, Aleena Akram, Sania Akram, Furqan Yaqub   +7 more
doaj   +1 more source

Mechanoactive Biomaterials for Cell–Matrix Mechanotransduction

Advanced Materials, EarlyView.
The graphical abstract shows how individual triggers (force, light, or temperature) and combined optothermal or receptor‐targeted actuation induce material responses at the tissue, cellular, and receptor scales. Their spatial (global or focused) and temporal (continuous or cyclic) modulation determines the resulting mechanical output.
Yi‐Tung Lu, Alison E. John, Marc A. Fernández‐Yagüe   +2 more
wiley   +1 more source